Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) rose 7.9% during mid-day trading on Wednesday . The stock traded as high as $13.93 and last traded at $14.06. Approximately 291,989 shares changed hands during trading, a decline of 75% from the average daily volume of 1,186,787 shares. The stock had previously closed at $13.02.
Analyst Upgrades and Downgrades
EWTX has been the topic of several research reports. HC Wainwright started coverage on shares of Edgewise Therapeutics in a report on Monday, June 30th. They set a "buy" rating and a $42.00 price objective on the stock. Scotiabank downgraded shares of Edgewise Therapeutics from a "sector outperform" rating to a "sector perform" rating and lowered their target price for the company from $50.00 to $14.00 in a research note on Wednesday, April 2nd. Guggenheim started coverage on shares of Edgewise Therapeutics in a research note on Wednesday, April 30th. They issued a "buy" rating and a $41.00 target price for the company. Royal Bank Of Canada restated an "outperform" rating and issued a $48.00 target price on shares of Edgewise Therapeutics in a research note on Thursday, June 5th. Finally, Piper Sandler restated an "overweight" rating and issued a $51.00 target price on shares of Edgewise Therapeutics in a research note on Wednesday, April 2nd. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $40.00.
View Our Latest Report on EWTX
Edgewise Therapeutics Stock Down 1.6%
The company's 50 day moving average price is $14.41 and its 200 day moving average price is $20.10. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -8.95 and a beta of 0.25.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.02. As a group, analysts expect that Edgewise Therapeutics, Inc. will post -1.45 earnings per share for the current year.
Insider Buying and Selling at Edgewise Therapeutics
In other news, insider Alan J. Russell sold 1,551 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $16.45, for a total transaction of $25,513.95. Following the completion of the sale, the insider owned 18,521 shares of the company's stock, valued at $304,670.45. The trade was a 7.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin Koch sold 4,276 shares of the business's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $16.45, for a total transaction of $70,340.20. Following the sale, the chief executive officer directly owned 20,619 shares of the company's stock, valued at $339,182.55. This represents a 17.18% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 14,258 shares of company stock worth $234,544. 23.20% of the stock is currently owned by company insiders.
Institutional Trading of Edgewise Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Baker BROS. Advisors LP increased its stake in shares of Edgewise Therapeutics by 5.4% during the fourth quarter. Baker BROS. Advisors LP now owns 6,155,940 shares of the company's stock worth $164,364,000 after purchasing an additional 315,881 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Edgewise Therapeutics by 9.3% during the fourth quarter. Janus Henderson Group PLC now owns 4,983,940 shares of the company's stock worth $133,044,000 after purchasing an additional 425,421 shares in the last quarter. Paradigm Biocapital Advisors LP increased its stake in shares of Edgewise Therapeutics by 61.1% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,493,929 shares of the company's stock worth $119,988,000 after purchasing an additional 1,704,757 shares in the last quarter. Cormorant Asset Management LP increased its stake in shares of Edgewise Therapeutics by 20.4% during the first quarter. Cormorant Asset Management LP now owns 4,101,992 shares of the company's stock worth $90,244,000 after purchasing an additional 695,458 shares in the last quarter. Finally, Braidwell LP increased its stake in shares of Edgewise Therapeutics by 5.4% during the first quarter. Braidwell LP now owns 2,458,808 shares of the company's stock worth $54,094,000 after purchasing an additional 126,612 shares in the last quarter.
About Edgewise Therapeutics
(
Get Free Report)
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
See Also
Before you consider Edgewise Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.
While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.